Latest Research Spotlight: Astaxanthin Bridges Therapy for Lung Cancer and Diabetes
Estimated Reading Time: 2 minutes
|A new peer-reviewed study published by Qian J et al explores the potential role of astaxanthin (AST) as a promising nutraceutical intervention in managing Lung cancer (LC) in the presence of Diabetes Mellitus (DM).
Lung cancer and diabetes mellitus are two widespread, life-altering diseases frequently occurring together and sharing similar underlying problems, from metabolic imbalances to chronic inflammation. Cutting-edge new research highlights how AST, a powerful natural carotenoid from sources like salmon and microalgae, may offer innovative protective solutions for both conditions.
What Was the Aim?
The study set out to explore how astaxanthin can simultaneously benefit those at risk of, or suffering from, both lung cancer and diabetes. Specifically, the review investigated AST’s ability to influence key metabolic, inflammatory, and cellular pathways that these diseases share.
How Was the Review Conducted?
Researchers conducted a comprehensive review of recent scientific findings:
-
They examined epidemiological data describing the overlap of lung cancer and diabetes in patients.
-
They explored laboratory and clinical studies showing how astaxanthin impacts pathways involved in glucose metabolism, oxidative stress, mitochondrial health, and inflammatory signaling.
-
The review also discussed advances in AST delivery methods, such as nano-emulsions to boost its effectiveness and bioavailability.
Key molecular signaling pathways targeted included PI3K/Akt/mTOR, AMPK, Nrf2/Keap1, and NF-κB—all crucial in both cancer and diabetes development.
What Were the Results?
-
Dual Protective Effects: AST was shown to reduce hyperglycemia-induced damage (benefiting diabetes) and limit the proliferation and survival of cancer cells (benefiting lung cancer).
-
Molecular Modulation: AST positively influenced glycolysis, oxidative phosphorylation, lipid metabolism, and autophagy—helping restore cellular balance.
-
Cellular Signaling: AST's actions on PI3K/Akt/mTOR, AMPK, Nrf2/Keap1, and NF-κB pathways contributed to decreased inflammation, improved mitochondrial function, and protection against oxidative stress.
-
Anti-Tumor Activity: Laboratory studies with lung cancer cells showed that AST inhibited cell proliferation and triggered cancer cell death.
-
Enhanced Delivery: Advanced methods like nanoemulsion encapsulation improved AST’s stability and absorption, enhancing its therapeutic effects.
-
Safety and Promise: Review of multiple human studies showed AST is safe even at higher-than-recommended doses.
What’s the Takeaway?
This comprehensive review suggests that astaxanthin holds real promise as a dual-action nutraceutical for those facing lung cancer, diabetes, or both. By targeting shared metabolic and inflammatory pathways, astaxanthin not only helps stabilize blood sugar and mitigate diabetes-related damage but also exerts anti-cancer actions.
While further clinical studies are needed to validate its use in humans, astaxanthin stands out as a potential natural intervention for integrated metabolic and cancer care.
Read the full study here:
International Immunopharmacology – Astaxanthin in Lung Cancer and Diabetes
Keep following Wellness Extract’s research column for the finest incredible, science-backed wellness insights from around the world.
